GLP-1 Market
LLY $1410.99 ▼ -0.5% NVO $40.45 ▲ +1.1% PFE $30.67 ▲ +0.5% VKTX $26.83 ▼ -1.6% KLRA $12.15 ▼ -5.5% GPCR $20.47 ▼ -6.4% RHHBY $60.68 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Romosozumab and Denosumab

Company
Massachusetts General Hospital
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026

Find a Clinical Trial Near Me

See recruiting studies for Romosozumab and Denosumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06938152

    Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

    Not yet reported National Taiwan University Hospital 70 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Osteoporosis, Osteoporosis Postmenopausal
    View official trial listing →
  • Recruiting NCT NCT07283887

    Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

    Not yet reported National Taiwan University Hospital 90 participants Est. completion 2026-07-31 1 site
    Other conditions: Osteoporosis
    View official trial listing →
  • Active, not recruiting NCT NCT05010590

    Anabolic Therapy in Postmenopausal Osteoporosis

    Not yet reported Massachusetts General Hospital 50 participants Est. completion 2027-11-01 1 site
    Other conditions: Postmenopausal Osteoporosis
    View official trial listing →
  • Not yet recruiting NCT NCT06720350

    Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures

    Not yet reported Marmara University 60 participants Est. completion 2026-12-15 1 site
    Other conditions: Osteoporosis in Post-menopausal Women
    View official trial listing →
  • Not yet recruiting NCT NCT07909304

    Romosozumab and Denosumab Combination Therapy for Osteoporosis

    Not yet reported Massachusetts General Hospital 100 participants Est. completion 2030-12
    Other conditions: Postmenopausal Osteoporosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.